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Introduction
Autologous chondrocyte implantation (ACI) has become a clinical standard therapy for articular cartilage repair in the past decades. However, limited amount of cartilage that can be harvested for cell extraction, morbidity at the harvest site, and dedifferentiation of chondrocytes during culture expansion have prompted investigation of more readily available cell types. Mesenchymal stromal cells (MSCs) have attracted considerable attention since they can be isolated from bone marrow and liposuction aspirates which are obtainable in substantial volumes by marginally invasive procedures. As skeletal progenitor cells, bone marrow-derived MSCs (BMSCs) comprise the inherent capacity to form cartilage and bone, while adipose tissue-derived stromal cells (ASCs) need additional priming or induction to differentiate towards the osteochondral lineage [1] . Both, BMSCs and ASCs have entered 2, 3] .
in vitro chondrogenesis of human MSCs [4] . Bone morphogenetic proteins (BMPs)-2, 4, and 6 can additionally stimulate chondrogenesis [5 chondrogenesis of human BMSCs and ASCs in the absence of TGF- [6, 7] . However, TGFdoes not induce MSCs to form stable hyaline cartilage and cells rather undergo, in vitro, a 8 cartilage tissue engineering to identify alternative growth factors or small molecules with the ability to induce a stable chondrogenic phenotype by suppressing cell progression into hypertrophy and preventing mineralization of the extracellular matrix.
Retinoic acid -an active vitamin A metabolite -is known to have a profound impact on early skeletal development; and growth plate chondrogenesis is particularly sensitive for retinoid misregulation [9] . Retinoid signaling affects several signaling molecules related to chondrogenesis including BMPs [10, 11] , matrix metalloproteinases (MMPs, including MMP13) [12] , parathyroid hormone-related protein (PTHrP) [13] , insulin-like growth factors 1 and 2 [14] , insulin-like growth factor binding proteins [15, 16] , and indian hedgehog (IHH) [17] . Retinoic acid receptor (RAR) antagonists have been shown to promote chondrogenic differentiation of mouse limb bud mesenchymal cultures [18, 19] and to prevent chondrocyte hypertrophy in developing chick limbs [20, 21] . It would therefore be highly interesting to investigate whether RAR antagonists could possibly induce stable MSC chondrogenesis by suppressing hypertrophy and endochondral development of cells. Data on retinoic acid signaling in human MSC cultures are, however, sparse and contradicting. In one report, the RAR antagonist LE135 promoted human BMSC chondrogenesis in monolayer culture [22] , while another study found LE135 to inhibit the TGF--mediated chondrogenic induction of BMSCs in 3D micromass pellet culture [23] . While cartilaginous matrix deposition remained 22], the second report was restricted to short-term mRNA data only (day 8) and did neither assess extracellular collagen type II deposition nor the chondrogenic phenotype of the cells [23] .
In view of these limited and puzzling results, we aimed to investigate whether antagonizing RAR with LE135 would be able to drive or improve chondrogenesis of human BMSCs and ASCs in a standard pellet culture model by stimulating cartilaginous matrix deposition during chondrogenesis or by inhibiting the TGF--driven hypertrophic differentiation of the chondrocytes.
expanded in an optimized expansion medium established before [25] that consisted of DMEM high glucose w/o L-glutamine, 12.5% fetal bovine serum (FBS), 2 mM L-glutamine, 1% non-essential amino acids, 50 passages before introducing into experiments.
ASCs were isolated from lipoaspirates obtained during liposuction of 2 female donors (age of 36 and 59) by collagenase (type B, 0.6 mg/mL, Roche Diagnostics, Germany) digestion and expanded as previously described [24] . ASCs were subcultured for 1-2 passages before introduced into experiments.
Written consent was obtained from all tissue donors and the study received approval from the local ethics committee.
To assess cytotoxicity of LE135, BMSCs from one donor were seeded into 6-well plates (2x10 4 /cm 2 ). After cell adhesion, medium was supplemented with 0.1 μM LE135 (Tocris biosciences, R&D Systems, Germany), 1 μM LE135, or the equivalent amount of dimethyl sulfoxide (Sigma-Aldrich) solvent (n=5 per group). After 48h incubation, cells in the supernatant and adherent cells were harvested and stained with 1 μg 7-amino-actinomycin D (7-AAD, eBioscience) according to the manufacturer's instructions. The Analyzer 10.
Chondrogenic differentiation in micromass pellet cultures
For chondrogenic differentiation, 5 10 5 expanded BMSCs or ASCs were centrifuged to form a micromass pellet and cultured in chondrogenic basal medium consisting of DMEM high glucose supplemented with 0.1 μM dexamethasone, 0.17 mM ascorbic acid 2-phosphate, 5 μg/mL transferrin, 5 ng/mL sodium selenite, 1 mM sodium pyruvate, 0.35 mM proline, 1.25 mg/mL bovine serum albumine (all from Sigma-Aldrich), 5 μg/ mL insulin (Lantus ® 6 weeks. Samples were divided into 7 treatment groups and received the following additional supplements of DMSO solvent as control. We designated the group treated with TGF-+ DMSO solvent as positive control and the group treated with DMSO as non-induced control. ASCs received 10 ng/mL BMP-6 in addition to TGF-1 where applicable [7] . Medium was changed thrice a week, and culture supernatants of all pellets of each group were pooled and frozen at -20°C.
Analysis of cell proliferation during differentiation
To visualize cell proliferation in pellets, newly synthesized DNA in pellets of one BMSC donor was labeled for 24h by incorporation of 5-iodo-2'deoxyuridin (IdU, MP Biomedicals) at days 0, 7, 9, 14, and 21 of treatment with either TGF-+ solvent (positive control) or TGF-+ 1 μM LE135. Pellets were subsequently BrdU antibody (Becton Dickinson) and a Cy3-labeled donkey anti-mouse secondary antibody (Jackson Immunoresearch), as reported previously [25] .
Analysis of chondrogenic differentiation
For histological analysis, two pellets of each experimental group were washed with phosphate buffered were stained with alcian blue (1%, Sigma-Aldrich) and counterstained with nuclear fast red (Chroma, Germany). Type I and II collagens were stained with mouse anti-human monoclonal antibodies (MP Biomedicals, Germany) according to standard immune histology protocols with fast red counterstaining (Roche Diagnostics, Germany).
Alkaline phosphatase (ALP) was assessed as parameter for hypertrophic differentiation. ALP activity also measured in pooled cell culture supernatants via conversion of the substrate p-nitrophenyl phosphate (Sigma-Aldrich). Fold changes were expressed relative to values of pellets from standard culture (TGF-in chondrogenic medium, no solvent). To assess gene expression levels, 4 pellets per donor and experimental group were pooled in order Trifast (peqGOLD, Peqlab, Germany) following standard guanidinium thiocyanate/phenol extraction protocols. Polyadenylated mRNA was isolated from total RNA using oligo d(T) coupled magnetic beads (Dynabeads; Dynal, Life Technologies) according to the manufacturer's instruction and reverse-transcribed (Omniscript ® genes of interest (Table 1) were analyzed for each donor separately by quantitative PCR using LightCycler TM technology (Roche Diagnostics). Relative gene expression was calculated by the C t method using -actin as reference gene. Data were expressed relative to values of pellets from standard culture (TGF-in chondrogenic medium, no solvent) set as 1.
Statistical analyses
(1.5 of the different treatment groups, a Kruskal-Wallis-Test with post-hoc Mann-Whitney-U Signed-Rank Tests was conducted comparing the treatment groups (n=5-7) to the TGF-(+ solvent, BMP-6) control group.
Results

LE135 inhibits TGF-ß-driven chondrogenic matrix deposition
To assess cytoxicity of LE135, BMSC monolayer cultures from one donor were treated with 0.1 μM LE135, 1 μM LE135, or the equivalent amount of DMSO solvent for 48h and cells were stained subsequently with 7-AAD. Flow cytometry revealed a median percentage of dead cells of 4.8% for 0.1 μM LE135, 4.3% for 1 μM LE135, and 5.7% for DMSO solvent (data not shown). In comparison, untreated cultures contained 5.7% dead cells (median). This indicates that treatment with LE135 in either concentration as well as DMSO solvent was not cytotoxic.
BMSC and ASC micromass pellets were exposed to chondrogenic medium supplemented with LE135 (0.1 μM or 1 μM), TGF-(10 ng/mL + equivalent amount of solvent), or solvent only. After six weeks, pellets treated with LE135 (0.1 or 1 μM) contained neither sGAGs, nor Fig. 1) showing that LE135 cannot induce chondrogenesis. To assess whether LE135 would promote TGF--driven chondrogenesis, pellets were co-treated with LE135 (0.1 μM or 1 μM) and TGF-in chondrogenic medium. Remarkably, LE135 completely inhibited the TGF--mediated deposition of sGAGs and collagen type II, demonstrating that already a low LE135 concentration, given from day 0, Collagen type I deposition apparently was possible when pellets were exposed to TGFplus either LE135 concentration. Recently, we reported that active cell proliferation during MSC differentiation is an indispensible requirement for successful chondrogenesis and involves a transient proliferation phase [25] . Proliferation is chondrogenesis across the whole pellet and subsequently decreases rapidly becoming restricted primarily to the periphery of the pellets during the following days. Between days 14 and 35, cells in distinct regions in the inner part of the pellets transiently resume cell division. By day 35 of chondrogenesis, proliferation has usually completely stopped throughout the pellets [25] . In order to assess whether treatment with LE135 would permit or abolish cell proliferation, newly synthesized DNA was labeled with IdU at days 0, 7, 9, 14, and 21 of treatment with either TGF-+ solvent (positive control) or with TGF-+ 1 μM LE135. Irrespective of the treatment, IdU-positive cells were evident at all assessed time points in a similar distribution as described above, showing proliferation in the pellet interior only on day 0 (data not shown), cell division in peripheral areas on days 7, 9 and 14, and single spots throughout the pellets on day 21 (Fig.  2) . This indicates active cell proliferation both in the positive control pellets and under cotreatment with TGF-+ 1 μM LE135.
Strong suppression of COL2A1 gene expression by LE135
Consistent with histology, pellets treated with LE135 showed as low COL2A1 mRNA levels at six weeks as non-induced controls (no TGF-, no LE135). Compared to the positive control (+TGF-treated groups (p=0.018 for 0.1 μM LE135, p=0.006 for 1 μM LE135) (Fig. 3A) . Moreover, addition of LE135 to TGF--treated pellets strongly suppressed COL2A1 expression to levels 
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Cellular Physiology and Biochemistry -lets co-treated with 1 μM LE135 plus TGFcompared to non-induced controls (3.8-fold, p=0.007) in line with the collagen type I staining evident in histology.
Apparently, LE135 affected gene expression of COL10A1 in a similar manner like COL1A1 expression (Fig. 3C) . COL10A1 mRNA levels remained at levels of non-induced controls under treatment with LE135 pellets induced with TGF-(0.1 μM LE135: 7.6-fold, p=0.018; 1 μM LE135: 38.5-fold, p=0.004). Again, during co-treatment with TGF-, only the high LE135 concentration levels compared to the positive control (3.1-fold, p=0.038) while 0.1μM LE135 was insufdriven COL10A1. In spite of detection of COL10A1 on the mRNA level, collagen type X protein deposition was below the detection limit of immune histology -trophic (COL10A1) development.
Effect of LE135 on hypertrophic markers
(IHH), matrix metalloproteinase-13 (MMP13), and alkaline phosphatase (ALPL) were little affected by LE135 (Fig. 4) . Neither 0.1 μM nor 1 μM LE135 induced expression of any one pellets induced with TGF-. Interestingly, LE135 addition to TGF--treated pellets -albeit preventing chondrogenic matrix deposition -did not reduce expression of IHH, MMP13, and ALPL. Instead, expression of these genes was high in all TGF--treated groups irrespective of LE135 addition.
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In agreement with ALPL gene expression (Fig. 4C) , alkaline phosphatase (ALP) enzyme activity (Fig. 4D ) in cell culture supernatants on day 24 of induction was in the range of nonlower than in pellets induced with TGF-(0.1 μM LE135: 48.1-fold, p=0.009; 1 μM LE135: 72.5-fold, p=0.009). Moreover, addition of LE135 to TGF--treated pellets had little effect. differentiation markers. Histological staining of ALP activity in pellets after 6 weeks of
Effect of LE135 on expression of signaling molecules
As established before, BMP4 is upregulated during MSC chondrogenesis (unpublished results) and could therefore potentially contribute to induction of hypertrophy. BMP4 expression was increased in BMSCs at six weeks compared to non-induced controls (5.7-fold, p=0.014) (Fig. 5A ). Under treatment with LE135, BMP4 expression, however, remained at control levels. When LE135 was added to TGF--treated pellets, BMP4 expression remained as high as under treatment with TGFto non-induced controls for 0.1 μM LE135 (8.9-fold, p=0.009) and for 1 μM LE135 (3.2-fold, thus, transcription of its target, the RAR receptor (Fig. 5B) . This was seen in the absence as well as in the presence of TGF-. Transcript levels of FOS (FBJ murine osteosarcoma viral oncogene homolog), a subunit of the activator protein (AP)-1 transcription factor, -treated pellets in either concentration (Fig. 5C) . Overall, these data indicated that BMP4, RARB, and FOS were little affected by LE135.
Discussion
In this study, we investigated whether modulation of RA signaling with an RAR antagonist is a promising approach to either drive or improve chondrogenesis of human MSCs in vitro. Opposite to previous studies [22, 23] we here used standard long term chondrogenic pellet culture to investigate the effect of the synthetic RAR antagonist LE135 on chondrogenesis, cartilaginous matrix deposition and cell phenotype of human BMSCs and ASCs in vitro. Our data show that LE135 is no promising inducer or stimulator of MSC chondrogenesis as 22] and can neither replace nor promote TGF-action which is believed to unfortunately contribute to cell hypertrophy. Strikingly, LE135 even blocked chondrogenic TGF-effects and completely inhibited TGF--induced deposition of cartilagecartilage, bone) and collagen type X (hypertrophic cartilage) was less sensitive to LE135
In line with Li et al., markers associated with endochondral differentiation like IHH (early hypertrophy), ALP (calcifying cartilage, bone), and MMP13 (hypertrophic chondrocytes) markers were already blocked at a low LE135 concentration while undesired components responded only at the high LE135 dose or were not affected at all. LE135 was therefore capable of uncoupling the induction of chondrogenic matrix deposition from endochondral differentiation, however not as desired for our purpose. Instead of blocking hypertrophy and collagen types I and X more effectively than cartilaginous matrix deposition, the induced effects were opposed to the desired direction. LE135 was here therefore not helpful to guide chondrocyte maturation away from endochondral development towards differentiation into a stable articular cartilage phenotype by preventing hypertrophic maturation and 
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In vivo, retinoids are essential for skeletal development [26] [27] [28] and the phase of growth plate chondrogenesis is particularly susceptible for retinoid misregulation [9] . Retinoid effects have been suggested to result from inhibition of prechondrogenic cell differentiation into chondroblasts [18, 29] and stimulation of chondrocyte maturation during endochondral bone formation [20] . Therefore, inducing opposite effects, i.e. promoting chondrogenic retinoid antagonists appeared attractive for overcoming current limitations of in vitro MSC chondrogenesis. However, retinoid acid signaling is complex and comprises trans-activating heterodimerically combine with retinoid X receptors (RXR).
In absence of retinoid agonists, unliganded RAR/RXR heterodimers bind to retinoic acid responsive elements (RARE) of target genes and recruit transcriptional co-repressors that repress gene expression [30] [31] [32] . Retinoid binding to RAR/RXRs induces a conformational change, whereupon co-repressors are released in favor of co-activators which induce transcriptional activation of target genes. Being a structural retinoid analog, the RAR antagonist LE135 can bind to RAR , however, its conformational restriction does not allow transcriptional activation. Thus, LE135 inhibits RARE-mediated trans-activation of direct retinoid target genes [33] .
We chose in vitro chondrogenic differentiation of BMSCs and ASCs. This culture system is an attractive model, because in contrast to in vivo since the chondrogenic medium does not contain any retinoids nor precursor molecules, and mammalian cells are incapable of de novo retinoid synthesis [34] . Consequently, there is no RAR trans-activity to be blocked by LE135 except for some initial carry-over of retinoids with quiescent RAR /RXR trans-activation, we did not observe LE135-mediated suppression of mRNA levels of RARB which is known as a direct target gene of RAR signaling containing a RARE in its regulatory region [35] .
Binding of LE135 to retinoid receptors may, thus, in our model predominantly exert its trans-repressive effects on other signaling cascades by competing for common co-repressors or direct protein-protein interaction. The currently best-described trans-repressive retinoid effect is the inhibition of activator protein (AP)-1 activity [36, 37] and LE135 has been reported to be capable of mediating AP-1 trans-repression [33] . In agreement with the common concept that AP-1 trans-repression occurs via direct or indirect interactions on the protein level [38] , we observed no repression of the AP-1 subunit FOS on mRNA level.
AP-1 plays a fundamental role for cellular proliferation [39] , and indirect blocking of AP-1 via LE135 in this study could therefore hypothetically inhibit or reduce proliferation during chondrogenic differentiation in MSC pellet cultures. Importantly, in vitro chondrogenic differentiation of MSCs involves active cellular proliferation and we recently demonstrated that cell division is an indispensible requirement for successful chondrogenic differentiation [25] . According to IdU staining, LE135 treatment in this study did not abolish cell proliferation, moderate anti-proliferative activity of LE135, thus impairing chondrogenesis, cannot be ruled out.
AP-1 is a target of both the non-canonical TGF-signaling [40] and the canonical, Smad-mediated TGF-pathway [41] [42] [43] [44] . Indeed, retinoid inhibition of chondrogenesis has been described to be mediated by down-regulation of the TGF-/Smad signaling in mouse cell lines [45, 46] . By putatively blocking AP-1 with LE135, we potentially signals that cooperate with AP-1, leaving others that are independent of AP-1 unaffected. Notably, TGF-signaling during MSC chondrogenesis is still incompletely assessed and the individual role of each of the multiple TGFsignaling pathways for driving the diverse stages of in vitro chondrogenesis (condensation, proliferation and apoptosis, matrix deposition, endochondral differentiation) remains signaling pathways, we observed differential effects of LE135 on individual TGF--induced cellular processes. According to our data, cartilaginous matrix deposition and especially COL2A1 expression is apparently mediated by a TGF--induced signaling cascade overlapping with RAR (AP-1) signaling, while hypertrophic maturation (except collagen type X) is putatively mediated by a distinct rather RAR-independent TGF-signaling pathway.
According to the hypothesis that LE135 inhibits AP-1 activity, direct AP-1 target genes containing AP-1 binding sites in their regulatory regions should be repressed in our study. Importantly, the COL10A1 enhancer region contains an AP-1 site [47] , and indeed, COL10A1 expression was reduced by a high concentration of LE135. However, LE135 inhibition of COL10A1 was far less pronounced than suppression of COL2A1, for which no AP-1 site is known. This indicates a higher grade of complexity of trans-repressing LE135 signaling not only via AP-1.
Taking the evident heterogeneity of MSC pellet cultures into consideration, our observations may also be explained by a differential sensitivity of MSC sub-populations proceeding down different lineages. With regard to this model, our data indicate, that cells differentiating chondrogenically were strongly affected by LE135 while osteogenic cells were insensitive to LE135. Further experiments are clearly needed to elucidate the precise signaling mechanism underlying the observations of this study.
Our gene expression results are in agreement with Li et al. who recently described data from early chondrogenesis (day 8) revealing inhibitory effects of LE135 (1 μM) on COL2A1, COL10A1, AGC, and TGFB expression in human BMSCs. In line with our results, they report that not all TGF-effects were blocked similarily and osteogenic gene expression remained unaffected. Together with our study, this demonstrates that RAR inhibition by LE135 seems to exert similar inhibitory effects on early differentiating cells and on cells at a more mature stage, leading overall to a complete block of MSC chondrogenesis. Stimulation of COL2A1 and AGC in human BMSC monolayer cultures at unaffected COL10A1 levels and LE135-induced cell differentiation in 3D scaffolds with only marginal deposition of cartilaginous matrix as 22] may be explained by the different culture conditions. In summary, we conclude that LE135 treatment is inadvisable during standard protocols of MSC chondrogenesis in vitro, because it strongly blocks phenotypic differentiation of the cells and deposition of a cartilaginous matrix. Notably, LE135 affected matrix deposition TGF-effects are sensitive to RAR while others are not. We hypothesize that blocking of only selected, AP-1-dependent TGF-signaling pathways contributes to this differential sensitivity. Overall, these results are highly interesting, because uncoupling the induction of the desired deposition of cartilaginous matrix from the concomitant induction of undesired collagen types and hypertrophic differentiation is a yet to overcome challenge for MSC chondrogenesis in vitro identify an agent that blocks the undesired hypertrophy while maintaining or strengthening cartilaginous matrix deposition. Since RAR was induced by TGF-and acts with differential effectiveness we suggest that RAR is an attractive target for future studies on suppressing endochondral differentiation. Indeed, a multitude of retinoid agonists and antagonists with selective activity on either RAR trans-activation or trans-repression have been described [33, 38] . Elucidation of the causative mechanism for the observed effects is therefore highly interesting and might uncover new possibilities to overcome current limitations of in vitro MSC chondrogenesis.
